Catalog #BP0146

InVivoPlus anti-mouse PD-1 (CD279)

Clone RMP1-14
Reactivities Mouse
Applications in vivo blocking of PD-1/PD-L signaling
in vitro Organoids/Organ-on-Chip
Isotype Rat IgG2a, κ

$895.50 - $6,295.00

$895.50 - $6.00

Choose an Option...
  • 100 mg - $6,295.00
  • 50 mg - $4,508.50
  • 25 mg - $3,056.50
  • 5 mg - $895.50
  • Custom Amount (Quotes Only)
In stock
Only %1 left
US Customers - Order within 1 hour, 14 minutes to receive by November 18.

Product Description

The RMP1-14 monoclonal antibody reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1’s structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease in mice as PD-1 knockout animals show dilated cardiomyopathy, splenomegaly, and loss of peripheral tolerance. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In mouse models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies are currently being explored as cancer treatments. Like the J43 antibody the RMP1-14 antibody has been shown to block the binding of both mouse PD-L1-Ig and mouse PD-L2-Ig to PD-1.

Specifications

Isotype Rat IgG2a, κ
Recommended Isotype Control(s) InVivoPlus rat IgG2a isotype control, anti-trinitrophenol
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Conjugation This product is unconjugated. Conjugation is available via our Antibody Conjugation Services.
Immunogen Syrian Hamster BKH cells transfected with mouse PD-1 cDNA
Reported Applications in vivo blocking of PD-1/PD-L signaling
in vitro Organoids/Organ-on-Chip
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin* ≤0.5EU/mg (≤0.0005EU/μg)
Determined by LAL assay
Aggregation* <5%
Determined by SEC
Purity ≥95%
Determined by SDS-PAGE
Sterility 0.2 µm filtration
Production Purified from cell culture supernatant in an animal-free facility
Purification Protein G
RRID AB_2894808
Molecular Weight 150 kDa
Murine Pathogen Tests* Ectromelia/Mousepox Virus: Negative
Hantavirus: Negative
K Virus: Negative
Lactate Dehydrogenase-Elevating Virus: Negative
Lymphocytic Choriomeningitis virus: Negative
Mouse Adenovirus: Negative
Mouse Cytomegalovirus: Negative
Mouse Hepatitis Virus: Negative
Mouse Minute Virus: Negative
Mouse Norovirus: Negative
Mouse Parvovirus: Negative
Mouse Rotavirus: Negative
Mycoplasma Pulmonis: Negative
Pneumonia Virus of Mice: Negative
Polyoma Virus: Negative
Reovirus Screen: Negative
Sendai Virus: Negative
Theiler’s Murine Encephalomyelitis: Negative
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
Need a Custom Formulation? See All Antibody Customization Options
* Additional quality control measures for our InVivoPlus™ products include advanced binding validation, murine pathogen screening, protein aggregation screening, and ultra-low endotoxin levels. The superior quality of our InVivoPlus™ products will meet and exceed the strict demands and rigorous standards required for in vivo research. Learn more about the InVivoPlus™ difference here.

Application References

  • in vivo blocking of PD-1/PD-L signaling
    Moynihan, K. D., et al (2016). "Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses" Nat Med. doi : 10.1038/nm.4200.

    Checkpoint blockade with antibodies specific for cytotoxic T lymphocyte-associated protein (CTLA)-4 or programmed cell death 1 (PDCD1; also known as PD-1) elicits durable tumor regression in metastatic cancer, but these dramatic responses are confined to a minority of patients. This suboptimal outcome is probably due in part to the complex network of immunosuppressive pathways present in advanced tumors, which are unlikely to be overcome by intervention at a single signaling checkpoint. Here we describe a combination immunotherapy that recruits a variety of innate and adaptive immune cells to eliminate large tumor burdens in syngeneic tumor models and a genetically engineered mouse model of melanoma; to our knowledge tumors of this size have not previously been curable by treatments relying on endogenous immunity. Maximal antitumor efficacy required four components: a tumor-antigen-targeting antibody, a recombinant interleukin-2 with an extended half-life, anti-PD-1 and a powerful T cell vaccine. Depletion experiments revealed that CD8+ T cells, cross-presenting dendritic cells and several other innate immune cell subsets were required for tumor regression. Effective treatment induced infiltration of immune cells and production of inflammatory cytokines in the tumor, enhanced antibody-mediated tumor antigen uptake and promoted antigen spreading. These results demonstrate the capacity of an elicited endogenous immune response to destroy large, established tumors and elucidate essential characteristics of combination immunotherapies that are capable of curing a majority of tumors in experimental settings typically viewed as intractable.

  • in vivo blocking of PD-1/PD-L signaling
    Zander, R. A., et al (2015). "PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity" Cell Host Microbe 17(5): 628-641.

    The differentiation and protective capacity of Plasmodium-specific T cells are regulated by both positive and negative signals during malaria, but the molecular and cellular details remain poorly defined. Here we show that malaria patients and Plasmodium-infected rodents exhibit atypical expression of the co-stimulatory receptor OX40 on CD4 T cells and that therapeutic enhancement of OX40 signaling enhances helper CD4 T cell activity, humoral immunity, and parasite clearance in rodents. However, these beneficial effects of OX40 signaling are abrogated following coordinate blockade of PD-1 co-inhibitory pathways, which are also upregulated during malaria and associated with elevated parasitemia. Co-administration of biologics blocking PD-1 and promoting OX40 signaling induces excessive interferon-gamma that directly limits helper T cell-mediated support of humoral immunity and decreases parasite control. Our results show that targeting OX40 can enhance Plasmodium control and that crosstalk between co-inhibitory and co-stimulatory pathways in pathogen-specific CD4 T cells can impact pathogen clearance.

  • in vivo blocking of PD-1/PD-L signaling
    Triplett, T. A., et al (2018). "Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme" Nat Biotechnol 36(8): 758-764.

    Increased tryptophan (Trp) catabolism in the tumor microenvironment (TME) can mediate immune suppression by upregulation of interferon (IFN)-gamma-inducible indoleamine 2,3-dioxygenase (IDO1) and/or ectopic expression of the predominantly liver-restricted enzyme tryptophan 2,3-dioxygenase (TDO). Whether these effects are due to Trp depletion in the TME or mediated by the accumulation of the IDO1 and/or TDO (hereafter referred to as IDO1/TDO) product kynurenine (Kyn) remains controversial. Here we show that administration of a pharmacologically optimized enzyme (PEGylated kynureninase; hereafter referred to as PEG-KYNase) that degrades Kyn into immunologically inert, nontoxic and readily cleared metabolites inhibits tumor growth. Enzyme treatment was associated with a marked increase in the tumor infiltration and proliferation of polyfunctional CD8(+) lymphocytes. We show that PEG-KYNase administration had substantial therapeutic effects when combined with approved checkpoint inhibitors or with a cancer vaccine for the treatment of large B16-F10 melanoma, 4T1 breast carcinoma or CT26 colon carcinoma tumors. PEG-KYNase mediated prolonged depletion of Kyn in the TME and reversed the modulatory effects of IDO1/TDO upregulation in the TME.

  • in vivo blocking of PD-1/PD-L signaling
    Mittal, D., et al (2014). "Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor" Cancer Res 74(14): 3652-3658.

    Adenosine targeting is an attractive new approach to cancer treatment, but no clinical study has yet examined adenosine inhibition in oncology despite the safe clinical profile of adenosine A2A receptor inhibitors (A2ARi) in Parkinson disease. Metastasis is the main cause of cancer-related deaths worldwide, and therefore we have studied experimental and spontaneous mouse models of melanoma and breast cancer metastasis to demonstrate the efficacy and mechanism of a combination of A2ARi in combination with anti-PD-1 monoclonal antibody (mAb). This combination significantly reduces metastatic burden and prolongs the life of mice compared with either monotherapy alone. Importantly, the combination was only effective when the tumor expressed high levels of CD73, suggesting a tumor biomarker that at a minimum could be used to stratify patients that might receive this combination. The mechanism of the combination therapy was critically dependent on NK cells and IFNgamma, and to a lesser extent, CD8(+) T cells and the effector molecule, perforin. Overall, these results provide a strong rationale to use A2ARi with anti-PD-1 mAb for the treatment of minimal residual and metastatic disease.

Product Citations

  • Endothelial cell cycle inhibition enables blood vessel maturation to normalize the tumor vasculature.

    In JCI Insight on 22 October 2026 by Cain, S. R., Genet, G., et al.

    PubMed

    Dysfunctional tumor vessels promote disease progression, whereas improved function enhances therapeutic delivery. However, current approaches to normalize tumor vasculature have limited efficacy. In vascular malformations, vessels are similarly dysfunctional, with endothelial cell (EC) hyperproliferation impairing arterial-venous specification. These defects are corrected with palbociclib, a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) that has beneficial effects on tumor and immune cells, but the effects on tumor vasculature are not well characterized. In our studies, murine mammary tumor ECs (TECs) exhibited disrupted cell cycle and specification, and CDK4/6i promoted TEC cycle control, enabling improved tumor vascular function. To investigate transcriptomic changes, we performed single-cell RNA sequencing (scRNA-seq) of treated and untreated tumors, and healthy tissues. CDK4/6i-mediated TEC cycle arrest promoted arterial-venous specification, cellular junctions, and pericyte association, and suppressed glycolytic and immunosuppressive gene expression. These effects were associated with increased vessel perfusion, decreased tumor hypoxia, and a more favorable immune landscape with immunotherapy. In scRNA-seq datasets from patients treated long-term with CDK4/6i, TECs exhibited similar transcriptomic changes associated with arterial-venous specification, pericyte recruitment, and immune signaling. Thus, in contrast to current strategies, CDK4/6i-mediated vascular changes may be maintained with continued treatment, highlighting the relevance of modulating TEC cycle to improve vessel maturation/function.

  • Matrix metalloproteinase-guided targeting of vesicular stomatitis virus to tumors following systemic administration.

    In Signal Transduct Target Ther on 20 October 2026 by Theune, E. V., Theune, W. C., et al.

    PubMed

    The lack of tumor-specific targeting by oncolytic viruses (OVs) restricts their therapeutic potential. Here, we report a "cap-linker" strategy to modify the vesicular stomatitis virus (VSV) glycoprotein (G protein, VSV-GIN). The modified VSV (Pro-VSVIN) loses its ability to infect cells until present in the tumor microenvironment, where the linker is cleaved by tumor-enriched matrix metalloproteinases (MMPs). When Pro-VSVIN is armed with a single-chain IL-12 (Pro-VSVIN-IL-12) and systemically injected into MC38 tumor-bearing mice, Pro-VSVIN-IL-12 eradicates established tumors while avoiding systemic toxicity, and elicits long-term anti-tumor immune memory. Systemic administration of Pro-VSVIN-IL-12 also markedly inhibits the growth of metastatic cancers in the lung. The efficacy of Pro-VSVIN-IL-12 was further improved when combined with PD-1 checkpoint blockade. Compared to WT VSVIN that carries IL-12, intravenously injected Pro-VSVIN-IL-12 leads to strong Th1 immunity, near abolishment of regulatory T cells, and potent CD8+ T cell activation and clonal expansion in tumors. This preclinical work demonstrates a new tumor-specific targeting strategy of VSV for enhanced immunotherapy safety with superior efficacy.

  • Distant lymph nodes compensate for resected tumor-draining lymph nodes during cancer immunotherapy.

    In Immunity on 13 October 2026 by Menzel, L., Zhou, H., et al.

    PubMed

    Surgical removal of tumor-draining lymph nodes (tdLNs) is commonly performed in cancer patients. Here, we investigated whether immune checkpoint blockade (ICB) responses persist after resection of tdLNs, important sites for the initiation and maintenance of anti-cancer immunity. Melanoma patients remained responsive to programmed death 1 (PD-1) blockade after regional LN dissection. Similarly, ICB efficacy persisted after tdLN resection in orthotopic murine melanoma and mammary carcinoma models. Following tdLN removal, interstitial fluid containing soluble antigen was diverted through interstitial spaces across lymphosome boundaries to distant LNs, wherein cancer-derived antigen was acquired and presented to T cells by LN-resident type I conventional dendritic cells. These responses persisted after primary tumor resection and supported ICB-induced systemic immunity. Locoregional delivery of ICB to compensatory LNs enhanced anti-cancer responses after tdLN resection. Consistently, ICB responses in head and neck cancer patients were associated with reactive LNs at distant sites. Thus, antigen rerouting enables distant LNs to compensate for resected tdLNs and sustain anti-cancer immunity, including responses enhanced by immunotherapy.

  • Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor.

    In Cell Rep Med on 15 September 2026 by Olson, D. J., Liu, B. A., et al.

    PubMed

    Enfortumab vedotin is a Nectin-4-directed antibody-drug conjugate designed to deliver the microtubule-disrupting agent monomethyl auristatin E (MMAE) to tumor cells. Using preclinical models of urothelial cancer (UC), we expand the understanding of the multifaceted mechanism of action for enfortumab vedotin that includes direct cytotoxicity on Nectin-4-positive tumor cells, indirect bystander effect on neighboring Nectin-4-negative tumor cells, and MMAE-mediated induction of immunogenic cell death (ICD) and associated increase in activated immune cells in the tumor microenvironment. Importantly, vaccination with enfortumab vedotin-treated tumor cells results in protection against tumor rechallenge in mice, consistent with antitumor immunity. MMAE-mediated ICD induction modulates the tumor microenvironment in a complementary manner to immune checkpoint inhibition. Accordingly, enfortumab vedotin plus PD-1 inhibitor shows enhanced antitumor activity in vivo. These preclinical findings provide mechanistic hypotheses that may be relevant to the improved clinical outcomes observed for enfortumab vedotin plus pembrolizumab relative to chemotherapy.

Product FAQs

Related Products

  1. Catalog #CP162
    RecombiMAb anti-mouse PD-1 (CD279) Read more
  2. Catalog #CP157
    RecombiMAb anti-mouse PD-1 (CD279) Read more
  3. Catalog #CP151
    RecombiMAb anti-mouse PD-1 (CD279) (D265A) Read more
  4. Catalog #SIM0010
    InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) Read more
  5. Catalog #SIM0003
    InVivoSIM anti-human PD-1 (Nivolumab Biosimilar) Read more
  6. Catalog #BP0273
    InVivoPlus anti-mouse PD-1 (CD279) Read more
  7. Catalog #BE0273
    InVivoMAb anti-mouse PD-1 (CD279) Read more
  8. Catalog #BP0033-2
    InVivoPlus anti-mouse PD-1 (CD279) Read more
  9. Catalog #BE0033-2
    InVivoMAb anti-mouse PD-1 (CD279) Read more
  10. Catalog #BE0193
    InVivoMAb anti-human PD-1 (CD279) Read more
  11. Catalog #BE0188
    InVivoMAb anti-human PD-1 (CD279) Read more
  12. Catalog #CP159
    RecombiMAb anti-mouse PD-1 (CD279) Read more
  13. Catalog #CP153
    RecombiMAb anti-mouse PD-1 (CD279) (LALA-PG) Read more
  14. Catalog #CP002
    RecombiMAb anti-mouse PD-1 (CD279) (D265A) Read more
  15. Catalog #CP005
    RecombiMAb anti-mouse PD-1 (CD279) (D265A) Read more
  16. Catalog #CP155
    RecombiMAb anti-mouse PD-1 (CD279) (LALA-PG) Read more
  17. Catalog #SIM0037
    InVivoSIM anti-human PD-1 (Cemiplimab Biosimilar) Read more
  18. Catalog #SIM0038
    InVivoSIM anti-human PD-1 (Tislelizumab Biosimilar) Read more
  19. Catalog #CP178
    RecombiMAb anti-mouse PD-1 (CD279) Read more
  20. Catalog #CP182
    RecombiMAb anti-mouse PD-1 (CD279) Read more
  21. Catalog #SIM0054
    InVivoSIM anti-human PD-1 (Sintilimab Biosimilar) Read more
  22. Catalog #CP185
    RecombiMAb anti-mouse PD-1 (CD279) Read more
  23. Catalog #CPB505
    Bispecific anti-mouse PD-1 x anti-mouse CTLA4 (LALA-PG) Read more
  24. Catalog #CPB515
    Bispecific anti-mouse LAG3 x anti-mouse PD-1 (LALA-PG) Read more
  25. Catalog #CP094
    RecombiMAb anti-mouse PD-1 (CD279) Read more
  26. Catalog #CPB522
    Bispecific anti-mouse LAG3 x anti-mouse PD-1 (LALA-PG) Read more
  27. Catalog #CP157FAB
    RecombiMAb anti-mouse PD-1 (CD279) F(ab) fragment Read more
  28. Catalog #CPB545
    Bispecific anti-mouse PD-1 x anti-mouse VEGF-A (LALA-PG) - PREORDER Read more

Additional Formats

  1. Catalog #BE0146
    InVivoMAb anti-mouse PD-1 (CD279) Read more
  2. Catalog #CP002
    RecombiMAb anti-mouse PD-1 (CD279) (D265A) Read more
  3. Catalog #CP094
    RecombiMAb anti-mouse PD-1 (CD279) Read more
  4. Catalog #CP151
    RecombiMAb anti-mouse PD-1 (CD279) (D265A) Read more
  5. Catalog #CP153
    RecombiMAb anti-mouse PD-1 (CD279) (LALA-PG) Read more
  6. Catalog #CP157
    RecombiMAb anti-mouse PD-1 (CD279) Read more
  7. Catalog #CP157FAB
    RecombiMAb anti-mouse PD-1 (CD279) F(ab) fragment Read more
  8. Catalog #CP162
    RecombiMAb anti-mouse PD-1 (CD279) Read more
  9. Catalog #CP182
    RecombiMAb anti-mouse PD-1 (CD279) Read more